AR and prostate carcinoma: Our previous studies have demonstrated that FKB is more potent in reducing cell viabilities of androgen receptor negative, castration resistant prostate cancer cell lines [13], and that FKB transcriptionally down-regulates the expression of androgen receptor and its target genes leading to inhibition of in vivo tumor growth in patient derived xenograft models [12].